Semax · ACTH(4-10) analog · pharmacokinetics · research use only
Semax half-life: minutes in plasma, longer in the literature.
Semax has one of the most misread kinetic profiles of any nootropic-class peptide. Measured in plasma, it clears in minutes — yet research describes central effects that persist well beyond that. The resolution is structural: Semax is ACTH(4-10) with a Pro-Gly-Pro tail that resists peptidase breakdown, giving it more stability than the native fragment it is built from, while studied downstream signalling outlasts the circulating peptide. This page explains why a short plasma half-life does not mean a short window of study, and is a laboratory reference, not a human protocol or medical advice.
Short in plasma — minutes
Like most small linear peptides, Semax is cleared from circulation rapidly — plasma clearance is reported on the order of minutes. If plasma concentration were the only variable, the compound would appear to act and vanish almost immediately. The reason it is studied on a longer functional window is structural, not a slower bloodstream clock — see the next card.
How that shapes timing →The Pro-Gly-Pro terminus
Semax is the ACTH(4-10) sequence with a C-terminal Pro-Gly-Pro addition. That tail resists enzymatic degradation, so Semax is reported to be meaningfully more stable than the native ACTH(4-10) fragment it derives from. The added stability is the structural reason its studied activity extends past what its raw plasma half-life alone would predict.
Why the sequence matters on a COA →Central effect outlasts plasma
The literature treats Semax's downstream central effects — including reported influence on neurotrophic signalling pathways — as outlasting the circulating peptide. That gap between plasma clearance and functional persistence is the same pattern seen with other peptides studied for tissue-level effects: two clocks, read separately.
Nootropic nasal peptides →Acute, pre-task timing in research
Because plasma exposure is short and intranasal absorption is fast, Semax research protocols tend to model acute, pre-task timing rather than building a steady-state level. The cadence follows the fast on/off plasma profile while accounting for the longer functional tail — distinct from a multi-day accumulation peptide.
Modelled timing →Identity, not just purity
Because Semax's stability advantage comes from a specific C-terminal addition, a sequence-confirming COA matters more than a bare purity number — a truncated or mis-synthesised peptide would not carry the same kinetics. Titan's Semax nasal spray ships with an HPLC main-peak result against a ≥99% internal purity target and mass-spec identity confirmation on a lot-matched release sheet.
See the testing workflow →Research-use framing
Semax is supplied strictly as a research-use-only reagent. The half-life and stability figures here are reproduced as a laboratory reference for in-vitro and modelling work — not instructions for human use, and not a claim about any cognitive or physiological effect. Nothing on this page is medical or dosing advice.
Research-use policy →The detail, in plain terms
Two clocks: plasma and function.
Semax's kinetics only make sense when rapid plasma clearance and the structural stability of the Pro-Gly-Pro terminus are read as separate variables. These are the figures a research protocol weighs, reproduced as a reference, not a human protocol.
- Compound
- Semax — ACTH(4-10) with a C-terminal Pro-Gly-Pro addition.
- Plasma clearance
- Short — reported on the order of minutes.
- Stability vs native fragment
- Greater than ACTH(4-10) — the Pro-Gly-Pro tail resists peptidases.
- Functional persistence
- Studied central effects reported to outlast plasma clearance.
- Resulting cadence
- Acute, pre-task timing in research — not multi-day accumulation.
- Titan format
- Metered nasal spray, $59.99 — no reconstitution required.
Questions researchers ask
Before you order.
- What is the half-life of Semax?
- Semax's plasma clearance is short — reported on the order of minutes, like most small linear peptides. However, the Pro-Gly-Pro addition at its C-terminus makes it more stable than the native ACTH(4-10) fragment, and studied central effects are reported to outlast the circulating peptide. The two figures describe different things: how fast it leaves the blood versus how long its functional effect is modelled to last.
- Why does Semax act longer than its plasma half-life suggests?
- Because of its structure. Semax is ACTH(4-10) with a C-terminal Pro-Gly-Pro tail that resists enzymatic degradation, giving it greater stability than the native fragment. Combined with downstream central signalling that the literature treats as outlasting the circulating peptide, the studied window is longer than raw plasma clearance alone would predict.
- How does the nasal spray fit Semax's kinetics?
- Intranasal delivery absorbs quickly, which matches Semax's fast on/off plasma profile. Research protocols tend to model acute, pre-task timing rather than building a steady-state level — the cadence follows the short plasma clock while accounting for the longer functional tail. See the Semax dosage reference for the modelled timing, framed as a laboratory reference.
- Why does Semax identity matter more than a purity number?
- Because its stability advantage comes from a specific C-terminal addition. A truncated or mis-synthesised peptide would not carry the same kinetics, so a sequence-confirming COA matters more than a bare purity figure. Titan's Semax ships with an HPLC main-peak result against a ≥99% internal purity target and mass-spec identity confirmation on a lot-matched release sheet.
- Is Semax approved for human use?
- Titan Peptide Lab supplies Semax strictly as a research-use-only reagent for in-vitro laboratory work — not for human or animal consumption, and not for diagnostic, therapeutic, or preventative use. The kinetic figures on this page are a laboratory reference, not medical or dosing advice.